GlassScriptPhysician profile
Angela Hardy
NPI 1174773824
$3,462.13
in general payments reported to CMS, 2019-2025
25 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $141 · 2022: $104 · 2023: $625 · 2024: $1,373 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,217.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $514.21 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $280.27 | 2021-2023 | Arexvy, Benlysta |
| Abbvie INC. | $250.00 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $250.00 | 2023-2024 | Dupixent |
| Inspire Medical Systems, INC. | $226.09 | 2023-2024 | Inspire |
| Hologic Sales and Service, LLC | $150.00 | 2024 | Aptima |
| Alexion Pharmaceuticals, INC. | $125.00 | 2023 | Ultomiris |
| Ardelyx, INC. | $125.00 | 2025 | Ibsrela |
| Kyowa Kirin, INC. | $125.00 | 2025 | |
| Neurelis, INC. | $125.00 | 2024 | Valtoco |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $125.00 | 2025 | |
| Itamar Medical INC | $125.00 | 2024 | Watchpatone |
| Phathom Pharmaceuticals, INC. | $125.00 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $125.00 | 2025 | Airsupra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $125.00 | 2025 | Nayzilam |
| Gilead Sciences, INC. | $119.78 | 2024 | Epclusa |
| Kestra Medical Technology Services, INC. | $74.30 | 2024-2025 | Assure Wcd |
| Axonics, INC. | $72.22 | 2022 | |
| Novo Nordisk INC | $71.26 | 2024 | Wegovy |
| Medtronic, INC. | $57.45 | 2024 | Linq II |
| Edwards Lifesciences Corporation | $55.09 | 2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $43.52 | 2024 | |
| Corium, LLC | $32.13 | 2022 | |
| Alkermes, INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Hardy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.